Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Flora Growth's share price for the quarter that ended in Jun. 2024 was $1.02. Flora Growth's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 13.37 Mil. Therefore, Flora Growth's market cap for the quarter that ended in Jun. 2024 was $13.63 Mil.
Flora Growth's quarterly market cap
increased
from Dec. 2023 ($12.06 Mil) to Mar. 2024 ($20.75 Mil) but then
declined
from Mar. 2024 ($20.75 Mil) to Jun. 2024 ($13.63 Mil).
Flora Growth's annual market cap
declined
from Dec. 2021 ($116.62 Mil) to Dec. 2022 ($30.86 Mil) and
declined
from Dec. 2022 ($30.86 Mil) to Dec. 2023 ($12.06 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Flora Growth's Enterprise Value for Today is $16.46 Mil.
Flora Growth Market Cap Historical Data
The historical data trend for Flora Growth's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Flora Growth's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Flora Growth's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flora Growth's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Flora Growth's Market Cap distribution charts can be found below:
* The bar in red indicates where Flora Growth's Market Cap falls into.
Flora Growth Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Flora Growth's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flora Growth (NAS:FLGC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Flora Growth Market Cap Related Terms
Thank you for viewing the detailed overview of Flora Growth's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FLGC has been successfully added to your 